Highlights

  • Biome Australia reported FY2026 Revenue of about AUD 23.9 million and net profit before tax of roughly AUD 1.2 million.
  • Gross Margin reached 62.1%, while adjusted EBITDA rose to around AUD 2.0 million.
  • The company is expanding its Activated Probiotics range across pharmacy channels and selected international markets.
  • Future progress depends on sustaining absolute profit growth, protecting margins and converting wider distribution into recurring sales.

Biome Australia Limited (ASX:BIO) is a consumer health company focused on live biotherapeutics and complementary medicines, led by its Activated Probiotics range. During FY2026, the Business moved further into profitability as revenue expanded and Operating Leverage improved. The key question now is whether the company can continue growing absolute Earnings while maintaining margins as it broadens distribution in Australia and overseas.

FY2026 Results Show a Clear Earnings Step-Up

For the year ended 30 June 2026, Biome reported revenue of about AUD 23.9 million. Net profit before tax reached roughly AUD 1.2 million, while adjusted earnings before interest, tax, Depreciation and Amortisation rose to around AUD 2.0 million. Gross margin was reported at 62.1%. These figures indicate that the company is not only increasing sales but also converting a greater share of its revenue base into operating earnings. For a smaller consumer health business, the more important signal is the rise in absolute profit rather than percentage growth rates that can appear exaggerated when measured from a low base.

Distribution and International Expansion Drive the Next Phase

Biome’s commercial engine is its Activated Probiotics portfolio, which is sold through community pharmacies and other health channels. The company has also been building distribution in markets including the United Kingdom, Ireland, Canada and New Zealand. International expansion gives the business additional room to grow beyond the domestic market, but it also adds execution, logistics and currency complexity. The next phase will depend on whether broader points of sale translate into repeat purchasing and whether the company can preserve its gross margin as volumes increase across different markets.

Growth Still Comes With Small-Cap Execution Risks

The company remains relatively small in absolute earnings terms, which means continued growth is important if profitability is to become more durable. Competition in probiotics and complementary medicines is significant, with pharmacy shelf space contested by established brands and new entrants. International growth introduces distributor and market-entry risk, while product development programs can require ongoing Investment without guaranteed commercial outcomes. Biome also has a clinical research program around its proprietary BMB18 strain, but that work should be viewed separately from the established commercial probiotics business because clinical development remains an earlier-stage source of optionality rather than current earnings.

Key Insights

Biome Australia’s FY2026 result shows a business progressing from early profitability toward a broader earnings base. Revenue of about AUD 23.9 million, net profit before tax of roughly AUD 1.2 million and adjusted EBITDA near AUD 2.0 million provide measurable evidence of that shift. The main indicators to watch are continued absolute profit growth, stable or improving margins, deeper pharmacy distribution and a larger contribution from international markets. The company’s challenge is to turn recent earnings progress into a repeatable pattern rather than rely on percentage growth from a small starting base.